GUT-108 / Gusto Global - LARVOL DELTA

"Hopefully, this bodes well for Dr. Sartor's GUT-103 and GUT-108 therapies." (@tpasinet)

Healthy Microbiome Designed by Gusto Global Shows Promise to Radically Change Treatment for Inflammatory Diseases (Businesswire) - "Gusto Global...has developed novel consortia of bacteria that shows promise as a 'breakthrough' therapy for treating Crohn’s disease and ulcerative colitis in patients. A new study published this month in Nature Communications by Gusto Global and top UNC-Chapel Hill scientists demonstrated that the live bacterial consortia, called GUT-103 and GUT-108, prevented and treated chronic immune-mediated colitis in humanized mouse models...GUT-108 is expected to advance into Phase 1 clinical trial."

Preclinical • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis